Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01057225 · OUTCOME

Overall Survival (12 Month)

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma · Source last updated 2017-12-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
From baseline to death

What was measured

12 Month Overall survival is defined as the proportion of patients to still be alive after 12 months.

Analysis population: All of the 64 participants that were eligible and began treatment were evaluated.

Groups in this outcome

All Treated Patients

Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Treated Patients64

Reported measurements

Source class 1
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
All Treated Patients96Not reported8699Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        86
        upper Limit
        99
        value
        96
denoms
  1. counts
    1. group Id
      OG000
      value
      64
    units
    Participants
description
12 Month Overall survival is defined as the proportion of patients to still be alive after 12 months.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.
    id
    OG000
    title
    All Treated Patients
param Type
NUMBER
population Description
All of the 64 participants that were eligible and began treatment were evaluated.
reporting Status
POSTED
time Frame
From baseline to death
title
Overall Survival (12 Month)
type
SECONDARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice